These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12970290)

  • 1. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women.
    Post MS; Verhoeven MO; van der Mooren MJ; Kenemans P; Stehouwer CD; Teerlink T
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4221-6. PubMed ID: 12970290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study.
    Verhoeven MO; Hemelaar M; van der Mooren MJ; Kenemans P; Teerlink T
    J Intern Med; 2006 Feb; 259(2):199-208. PubMed ID: 16420549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of hormone replacement therapy on blood platelets.
    Thijs A; van Baal WM; van der Mooren MJ; Kenemans P; Dräger AM; Huijgens PC; Stehouwer CD
    Eur J Clin Invest; 2002 Aug; 32(8):613-8. PubMed ID: 12190961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone replacement therapy and plasma homocysteine levels.
    van Baal WM; Smolders RG; van der Mooren MJ; Teerlink T; Kenemans P
    Obstet Gynecol; 1999 Oct; 94(4):485-91. PubMed ID: 10511346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women.
    Teerlink T; Neele SJ; de Jong S; Netelenbos JC; Stehouwer CD
    Clin Sci (Lond); 2003 Jul; 105(1):67-71. PubMed ID: 12625833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risk markers during treatment with estradiol and trimegestone or dydrogesterone.
    Hellgren M; Conard J; Norris L; Kluft C
    Maturitas; 2009 Mar; 62(3):287-93. PubMed ID: 19268506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: a randomized study.
    Verhoeven MO; Hemelaar M; Teerlink T; Kenemans P; van der Mooren MJ
    Atherosclerosis; 2007 Nov; 195(1):181-8. PubMed ID: 17084844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects on asymmetric dimethylarginine of HMR 3339, a novel selective estrogen receptor modulator: a 12-week, randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.
    Verhoeven MO; Teerlink T; Kenemans P; Vogelvang TE; van der Mooren MJ;
    Menopause; 2007; 14(2):235-42. PubMed ID: 17146377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone therapy and asymmetrical dimethylarginine in postmenopausal women.
    Karkanaki A; Vavilis D; Traianos A; Kalogiannidis I; Panidis D
    Hormones (Athens); 2010; 9(2):127-35. PubMed ID: 20687396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo- controlled, 12-week study in early postmenopausal women.
    Post MS; Hendriks DF; Van Der Mooren MJ; Van Baal WM; Leurs JR; Emeis JJ; Kenemans P; Stehouwer CD
    J Intern Med; 2002 Mar; 251(3):245-51. PubMed ID: 11886484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone.
    Norris LA; Brosnan J; Bonnar J; Conard J; Kluft C; Hellgren M
    Thromb Haemost; 2008 Aug; 100(2):253-60. PubMed ID: 18690345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women.
    Post MS; Rosing J; Van Der Mooren MJ; Zweegman S; Van Baal WM; Kenemans P; Stehouwer CD;
    Br J Haematol; 2002 Dec; 119(4):1017-23. PubMed ID: 12472583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism.
    Ozcan O; Cakir E; Yaman H; Akgul EO; Erturk K; Beyhan Z; Bilgi C; Erbil MK
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):203-6. PubMed ID: 16060915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asymmetric dimethylarginine plasma concentrations and L-arginine/asymmetric dimethylarginine ratio in patients with slow coronary flow.
    Selcuk MT; Selcuk H; Temizhan A; Maden O; Ulupinar H; Baysal E; Ozeke O; Sasmaz A
    Coron Artery Dis; 2007 Nov; 18(7):545-51. PubMed ID: 17925608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery.
    Maas R; Dentz L; Schwedhelm E; Thoms W; Kuss O; Hiltmeyer N; Haddad M; Klöss T; Standl T; Böger RH
    Crit Care Med; 2007 Aug; 35(8):1876-81. PubMed ID: 17581491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asymmetric dimethylarginine concentrations decrease in patients with HIV infection under antiretroviral therapy.
    Kurz K; Teerlink T; Sarcletti M; Weiss G; Zangerle R; Fuchs D
    Antivir Ther; 2012; 17(6):1021-7. PubMed ID: 22892398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules.
    Van Baal WM; Emeis JJ; Kenemans P; Kessel H; Peters-Muller ER; Schalkwijk CG; van der Mooren MJ; Stehouwer CD
    Eur J Clin Invest; 1999 Nov; 29(11):913-21. PubMed ID: 10583435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography.
    Teerlink T; Nijveldt RJ; de Jong S; van Leeuwen PA
    Anal Biochem; 2002 Apr; 303(2):131-7. PubMed ID: 11950212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of combined supplementation with B vitamins and antioxidants on plasma levels of asymmetric dimethylarginine (ADMA) in subjects with elevated risk for cardiovascular disease.
    Schmitt B; Wolters M; Kressel G; Hülsmann O; Ströhle A; Kühn-Velten WN; Lichtinghagen R; Bub A; Barth SW; Stichtenoth DO; Hahn A
    Atherosclerosis; 2007 Jul; 193(1):168-76. PubMed ID: 16876171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma markers of NO synthase activity in women after ovarian hyperstimulation: influence of estradiol on ADMA.
    Cevik D; Unay O; Durmusoglu F; Yurdun T; Bilsel AS
    Vasc Med; 2006 Feb; 11(1):7-12. PubMed ID: 16669407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.